Enveric Biosciences, Inc.

What they do

Enveric conducts preclinical research and development of small-molecule compounds intended to promote neuroplasticity without inducing hallucinations. Its lead program, the EVM301 Series, centers on EB-003, a novel DMT derivative designed to selectively engage 5-HT2A and 5-HT1B receptors. The company is conducting IND-enabling toxicology, safety pharmacology, ADMET and genotoxicity studies for EB-003. A second program, the EVM401 Series of methylone-inspired molecules, was unveiled in February 2025 but is not the primary focus.

Revenue drivers

• Pre-revenue drug development — Enveric has no product revenue; the company is advancing EB-003 and other candidates through preclinical studies toward IND submission and Phase 1 trials.
• EVM301 Series / EB-003 — Lead program and primary focus of spending; no commercial sales, with value contingent on regulatory approval and eventual commercialization.
• EVM401 Series — Additional non-hallucinogenic molecules targeting addiction and neuropsychiatric disorders; company intends to pursue but with lower prioritization than EB-003.

Recent performance

The reported XBRL financials show no annual revenue in 2021-2025 and net income of $-49.0M in 2021, $-18.5M in 2022, $17.5M in 2023, $9.6M in 2024, and $12.1M in 2025. Diluted EPS was $-36.24 in 2025. Operating cash flow was $-8.1M in 2025. As of June 30, 2026, total assets were $8.9M and shareholder equity was $8.1M. In its second-quarter 2026 earnings release, the company reported continued advancement of IND-enabling studies for EB-003 and new preclinical data on its non-hallucinogenic profile.

Strategy

Management's stated priority is to complete remaining IND-enabling activities for EB-003, submit an Investigational New Drug application, and initiate a first-in-human Phase 1 clinical trial. The company is also expanding its intellectual property portfolio, including a U.S. patent covering EVM301 Series methods of treating psychiatric disorders and a Notice of Allowance for the EVM401 Series. It plans to submit IND and eventual NDA filings with the FDA and other regulators. Management intends to continue developing the Psybrary compound library and may pursue in-licensing or collaborations.

Risks

• Going concern — The company states that factors exist that raise substantial doubt about its ability to continue as a going concern for one year from issuance of its unaudited condensed consolidated financial statements.
• Early-stage pipeline — EB-003 and other candidates remain preclinical and may not reach later development stages, receive regulatory approval, or be commercialized.
• Financing needs — The company has significant and increasing liquidity needs and may be unable to raise additional capital on acceptable terms, or at all; failure could require delaying or discontinuing operating activities.
• Competition and scientific uncertainty — Enveric expects intense competition, and future studies may dispute its beliefs about the medical benefits, safety, efficacy, or social acceptance of psychedelic-inspired drug candidates.

Outlook

Management says its priorities for the second half of 2026 are to complete remaining IND-enabling activities, submit the planned IND application for EB-003, and advance the candidate into a first-in-human clinical trial. The company cites recent FDA guidance on psychedelic drug development and strategic investment by major pharmaceutical companies as supportive of the neuroplastogenic field. It characterizes the quarter's preclinical data and patent progress as strengthening its lead program and broader platform. No revenue guidance is provided.